Medpace (NASDAQ:MEDP) CEO August Troendle Sells 15,609 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 15,609 shares of Medpace stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $606.47, for a total transaction of $9,466,390.23. Following the completion of the transaction, the chief executive officer owned 588,369 shares of the company’s stock, valued at $356,828,147.43. This trade represents a 2.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Medpace Price Performance

Shares of MEDP opened at $620.75 on Friday. The company has a market capitalization of $17.33 billion, a P/E ratio of 36.39, a PEG ratio of 2.73 and a beta of 1.15. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The business’s 50 day simple moving average is $550.16 and its 200-day simple moving average is $492.71.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same period last year, the firm posted $3.10 EPS. The business’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on MEDP. Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $535.00 price target on shares of Medpace in a research report on Thursday, July 23rd. BMO Capital Markets increased their price objective on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and raised their price objective for the company from $490.00 to $515.00 in a research report on Tuesday, July 7th. Finally, Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and an average target price of $584.18.

Institutional Trading of Medpace

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MEDP. BlackRock Inc. acquired a new position in Medpace during the 2nd quarter valued at about $1,323,047,000. AQR Capital Management LLC lifted its holdings in Medpace by 31.6% in the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after buying an additional 324,293 shares during the period. Wasatch Advisors LP grew its holdings in Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after acquiring an additional 116,354 shares during the period. Geode Capital Management LLC raised its position in shares of Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after acquiring an additional 24,625 shares during the last quarter. Finally, Invesco Ltd. grew its stake in shares of Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after purchasing an additional 85,517 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.